Paritaprevir could inhibit viral phosphoprotein NS5A and is significant to viral replication and other activities. It also has been found to have potential effect agains hepatitis C virus.
Paricalcitol Intermediate CD is an intermediate of paricalcitol, an analogue of vitamin D2. Paricalcitol is a medication used for the treatment of secondary hyperparathyroidism.
Paricalcitol Intermediate A is an intermediate of paricalcitol, an analogue of vitamin D2. Paricalcitol is a medication used for the treatment of secondary hyperparathyroidism.
Paricalcitol Impurity 4 is an impurity of paricalcitol, an analogue of vitamin D2. Paricalcitol is a medication used for the treatment of secondary hyperparathyroidism.
An impurity of Paricalcitol which is a man-made form of vitamin D to treat and prevent high levels of a certain natural substance made by the body (parathyroid hormone) in patients with long-term kidney disease.
An impurity of Parecoxib. The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells and rat brain tissue. Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days. The selective COX-2 inhibitor parecoxib was delivered 20 min before or 20 min after the incision by intraperitoneal injection. Pretreatment with parecoxib markedly attenuated the pain hypersensitivity induced by incision.
An impurity of Parecoxib. The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells and rat brain tissue. Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days. The selective COX-2 inhibitor parecoxib was delivered 20 min before or 20 min after the incision by intraperitoneal injection. Pretreatment with parecoxib markedly attenuated the pain hypersensitivity induced by incision.
Paquinimod, also known as ABR‑215757, belonging to the class of quinoline-3-carboxamide derivatives, is a S100A9 inhibitor. Paquinimod is an immunomodulatory compound that reduces pathology in experimental collagenase-induced osteoarthritis.
Pantoprazole EP Impurity E is an impurity of Pantoprazole, a first-generation proton pump inhibitor (PPI) used as a drug for the treatment of gastroesophageal reflux disease (GERD).
Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.
Monogalactosyldiacylglycerol (MGDG) and digalactosyldiacylglycerol (DGDG) are the two nonionic lipid constituents of the thylakoid membrane of higher plant chloroplasts. MGDG and DGDG are present in the membrane at 56% and 29%, respectively, of the total lipid content. DGDG is a bilayer-forming lipid, while MGDG alone will only form hexagonal-II structures.
Palmitoylethanolamide is an endogenous cannabinoid found in brain, liver, and other mammalian tissues. It is a weak ligand of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors, and a selective GPR55 agonist (EC50 values are 4, 19 800 and > 30 000 nM at GPR55, CB2 and CB1 receptors respectively). Nutritional supplement in health care products.
Palmatine hydrochloride (Palmatine chloride) is a hydrochloride salt of palmatine, a protoberberine alkaloid that has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases. It acts as an inhibitor of dopamine generation which reduces Ca2+ levels.
A metabolite of Paliperidone Palmitate, an impurity of Paliperidone which is a dopamine antagonist and 5-HT2A antagonist of the atypical antipsychotic class of medications.
Palifosfamide is a synthetic mustard compound with potential antineoplastic activity. An active metabolite of ifosfamide covalently linked to the amino acid lysine for stability, palifosfamide irreversibly alkylates and cross-links DNA through GC base pairs, resulting in irreparable 7-atom inter-strand cross-links; inhibition of DNA replication and cell death follow. Unlike ifosfamide, this agent is not metabolized to acrolein or chloroacetaldehyde, metabolites associated with bladder and CNS toxicities. In addition, because palifosfamide does not require activation by aldehyde dehydrogenase, it may overcome the tumor resistance seen with ifosfamide.
Palbociclib Impurity 2 is an impurity of Palbociclib, which is a selective cyclin-dependent kinases CDK4 and CDK6 inhibitor used for the treatment of ER-positive and HER2-negative breast cancer.
Palbociclib Impurity 10 is an impurity of Palbociclib, which is a selective cyclin-dependent kinases CDK4 and CDK6 inhibitor used for the treatment of ER-positive and HER2-negative breast cancer.
Pacritinib is an orally bioavailable and ATP-competitive inhibitor of JAK2 (IC50 = 23 nM), and also inhibits FLT3 (IC50 = 22 nM). It suppresses proliferation in cells carrying the JAK2V617F mutation.
An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer.
An impurity of Palbociclib, a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Palbociclib is developed for the treatment of ER-positive and HER2-negative breast cancer.
PA-824, a bioreductive drug. PA-824 has potent in vitro activity against Mycobacterium tuberculosis. PA-824 was tested in vitro against a broad panel of multidrug-resistant clinical isolates and was found to be highly active against all isolates (MIC<1 microg/ml). PA-824 showed significant activity at 2, 10, and 50 microg/ml, similar to that of metronidazole, in a dose-dependent manner.
P7C3-A20, an analogue of P7C3, is a neuroprotective compound which inhibits mature neuronal cell death while also increasing the net magnitude of postnatal neurogenesis in models of neurodegeneration and acute injury.
